Q2 2026 Danaher Corp Earnings Call Transcript
Key Points
- Danaher Corp (DHR) delivered a solid second quarter with better-than-expected revenue, earnings, and cash flow.
- Life Sciences businesses had their strongest quarter in several years, with notable growth in biotechnology and diagnostics.
- The acquisition of Masimo was completed earlier than expected and is anticipated to be immediately accretive to adjusted EPS.
- Core revenue in high-growth markets increased more than 10%, with significant growth in China.
- Danaher Corp (DHR) raised its full-year adjusted EPS guidance, reflecting confidence in accelerating revenue and earnings growth.
- Core revenues in developed markets declined slightly due to shipment timing in biotechnology and lower respiratory revenue year-over-year.
- Bioprocessing consumables growth came in below expectations due to customer project timing and shipment delays.
- Adjusted operating profit margin decreased by 20 basis points due to lower respiratory revenue year-over-year.
- The company faces a 250 basis point year-over-year headwind from respiratory testing in the third quarter.
- Academic and government markets remain below normal levels, impacting overall growth potential.
My name is Chelsea and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's second-quarter 2026 earnings results conference call. (Operator Instructions)
I will now turn the call over to Ms. Rachel Vatnsdal, Vice President of Investor Relations. Ms. Vatnsdal, you may begin your conference.
Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; and Matt Gugino, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, quarterly report on Form 10-Q, the slide presentation supplementing today's call the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call and a note containing details of historical and anticipated future financial performance are all available on the Investors section of our website,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
